Skip navigation |

Test effort in persons with CFS

Full Title: Test effort in persons with Chronic Fatigue Syndrome when assessed using the Validity Indicator Profile.

Authors: Cockshell SJ, Mathias JL.

Publication: Journal of Clinical abd Experimental Neuropsychology

Publication Date: 23rd March 2012

a School of Psychology , The University of Adelaide , Adelaide , SA , Australia.

Abstract

The current study examined the potential contribution of suboptimal effort to the cognitive deficits that are associated with Chronic Fatigue Syndrome (CFS) using the Validity Indicator Profile (VIP). Unlike most tests of effort, the VIP distinguishes between intentional and unintentional poor performance and does not assess cognitive functions that are affected by CFS, thereby reducing the risk of mistakenly attributing genuinely poor performance to reduced effort. The VIP was administered to 54 persons with CFS and 54 matched healthy community controls, and performance categorized into 1 of 4 response styles (valid: compliant; invalid: suppressed, irrelevant, inconsistent), based on the level of effort expended (high or low) and the intention to perform well or not. VIP performance was classified as valid for the majority of participants (CFS and controls), indicating high levels of effort and an intention to perform well. Three participants in the CFS group and four in the control group showed low levels of effort but an intention to do well (invalid: inconsistent). No participant performed in a manner indicative of an intent to perform poorly (invalid: suppressed, inconsistent). These findings suggest that poor effort is unlikely to contribute to cognitive test performance of persons with CFS.

PMID: 22440059

View the abstract in PubMed.

 

Back to top

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the Action for M.E. website. To find out more about the cookies, see our privacy policy.